WO2024094890A1 - Implant pour la réparation du cartilage et du ménisque - Google Patents

Implant pour la réparation du cartilage et du ménisque Download PDF

Info

Publication number
WO2024094890A1
WO2024094890A1 PCT/EP2023/080806 EP2023080806W WO2024094890A1 WO 2024094890 A1 WO2024094890 A1 WO 2024094890A1 EP 2023080806 W EP2023080806 W EP 2023080806W WO 2024094890 A1 WO2024094890 A1 WO 2024094890A1
Authority
WO
WIPO (PCT)
Prior art keywords
decm
implant
ink
cartilage
meniscus
Prior art date
Application number
PCT/EP2023/080806
Other languages
English (en)
Inventor
Daniel Kelly
Bin Wang
Xavier BARCELLO GALLOSTRA
Soraya SALINAS FERNANDEZ
Conor Buckley
Orchid GARCIA
Original Assignee
The Provost, Fellows, Scholars And Other Members Of Board Of Trinity College Dublin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Provost, Fellows, Scholars And Other Members Of Board Of Trinity College Dublin filed Critical The Provost, Fellows, Scholars And Other Members Of Board Of Trinity College Dublin
Publication of WO2024094890A1 publication Critical patent/WO2024094890A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3612—Cartilage, synovial fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3633—Extracellular matrix [ECM]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3641—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the site of application in the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/06—Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus

Definitions

  • the present invention relates to an implant for cartilage and meniscus repair.
  • the invention relates to an implant for repair of soft tissues in high-load synovial joints such as the meniscus of the knee joint.
  • US4880429A discloses a prosthetic meniscus comprising a porous dry volume matrix of type I collagen fibers interspersed with glycosaminoglycan molecules, wherein said matrix has a substantially wedge shape including a wide central region between two narrow distal tip regions, wherein said collagen fibers are present at a concentration of about 65%-98% by dry weight.
  • porous scaffolds are relatively soft compared to native meniscal tissue.
  • US4880429A does not disclose how to produce meniscal implants with biomimetic mechanical properties. Nor does it teach how 3D printing techniques can be used to produce implants with anisotropic structure and mechanics mimetic of the native meniscus.
  • CN111228574A describes a tissue engineered meniscus scaffold formed from a bioink comprising (a) hydrogel material (e.g. HA, alginate etc), (b) cells and (c) and a matrix material which could be dECM, and printing the bioink to form the scaffold.
  • the concentration of the matrix dECM is 0.5 to 2% (w/v).
  • KR20180049712A describes a cell containing bioink for 3-D wet printing.
  • the bioink may consist of dECM, or dECM combined with a water-soluble polymer.
  • concentration of the dECM is mentioned as being 1-5% and preferably 2-3%.
  • the method describes neutralising the bioink prior to addition of cells.
  • the construct is printed into a coagulation bath.
  • the bioink contains 3% collagen in addition to dECM, and the dECM/collagen mixture is printed into a coagulation bath at neutral pH.
  • CN112295015A describes a dECM bioink that comprises in addition to dECM an additional material such as polylactic acid or gelatin to the dECM to make the bioink.
  • dECM hydrogels and inks having a high concentration of dECM e.g. 5-10% w/v
  • optionally a high pH e.g. >10
  • the dECM inks and hydrogels of the invention have been used for high resolution printing of large acellular implants ( Figure 3) and casting of anatomically shaped meniscal implants into pre-formed moulds ( Figure 4.
  • Such dECM derived implants can be chemically crosslinked (e.g. using glutaraldehyde) during or after the fabrication process to improve the mechanical properties.
  • a dECM implant can be fabricated with different zones containing different structural and mechanical properties, to provide an environment that would mimic the native one ( Figure 9).
  • a more porous implant can be produced by freeze-drying the construct post-fabrication. In this scenario, chemically crosslinking the construct after freeze-drying produces an implant with superior mechanical properties (Figure 8).
  • the invention provides a decellularized extracellular matrix (dECM) ink comprising at least 5%, for example 5 to 10%, cartilage dECM and typically having a pH range from 4 to 12.
  • dECM decellularized extracellular matrix
  • ink is used to describe the dECM composition, but it could also be referred to as a slurry or a hydrogel as it generally has a viscosity of a gel or viscous slurry.
  • the dECM is cartilage or meniscus dECM.
  • the ink is an aqueous ink.
  • the dECM ink has a pH of 9 to 12 or 10 to 12.
  • the dECM ink has a pH of 10.5 to 11.5, or about 11. In any embodiment, the dECM ink comprises a salt.
  • the dECM ink comprises 10 mM to 300 mM salt.
  • the dECM ink comprises 100 mM to 200 mM salt.
  • the dECM ink comprises 125 mM to 175 mM salt.
  • the salt is a chloride salt such as, for example, sodium chloride.
  • the dECM ink does not comprise a second hydrogel.
  • the dECM ink does not comprise a second hydrogel comprising gelatin, hyaluronic acid, dextran or collagen.
  • the invention also provides an implant comprising (or formed from) dECM ink of the invention.
  • the implant is crosslinked.
  • the implant is freeze-dried. This makes the implant more porous and also reduced the water content of the implant making it more suitable for storage.
  • the implant may be snap-frozen prior to freeze-drying. When the implant is freeze-dried, it is generally re-hydrated prior to use.
  • the implant is crosslinked after freeze-drying. Surprisingly, performing crosslinking after the freeze drying process results in superior mechanical properties and elasticity in the implant.
  • the implant is chemically crosslinked with a chemical crosslinking agent.
  • the crosslinking agent can be natural and/or synthetic and may be selected from, among others, the following ones: genipin (GNP), riboflavin, tissue transglutaminase 2 (TG2), proanthocyanidin (PA), epigallocatechin gallate (EGCG), dehydrothermal treatment (DHT), glutaraldehyde, N-(3- Dimethyl aminopropyl)-N'-ethyl carbodiimide hydrochloride (EDC) and EDC with N hydroxysulfosuccinimide (EDC-NHS)
  • the implant is selected from a cast and a 3-D printed construct.
  • the implant comprises casted dECM ink.
  • the implant is casted in the shape of a natural cartilage tissue (for example in the shape of a meniscus of the knee, or knee articular cartilage).
  • the implant comprises 3-D printed dECM ink. This means that it is formed by 3D printing of a dECM ink.
  • the dECM ink is generally printed into fibres, which provides the implant with a fibrous structure.
  • the fibres may be arranged in a manner to mimic the arrangement of fibres in natural meniscus cartilage (see Figures 9 where the fibres are printed into an arc shape mimicking the arrangement of fibres in the meniscus of the knee).
  • the implant may comprise fibres having a first configuration and fibres having a second configuration.
  • a first set of fibres may be arranged to extend in a first Direction or orientation (e.g. circumferential fibres) and a second set of fibres may be arranged to extend in a second direction or orientation that is different to the first direction or orientation (e.g. radial fibres).
  • the first and second sets of fibres may be arranged in a lattice.
  • the implant is a fibrous implant, in which at least some of the fibres are formed by 3-D printing of a dECM ink of the invention.
  • the implant is a fibrous implant, in which: at least some of the fibres are formed by 3-D printing of a first dECM ink of the invention; and at least some of the fibres are formed by 3-D printing of a second dECM ink of the invention.
  • the first dECM ink has a first salt concentration and the second dECM ink has a second salt concentration that is different to the first salt concentration.
  • the first salt concentration may be less than 150 mM and the second salt concentration may be greater than 150 mM.
  • the first dECM ink has a first dECM concentration and the second dECM ink has a second dECM concentration that is different to the first dECM concentration.
  • the first dECM ink has a first salt concentration and a first dECM concentration and the second dECM ink has a second salt concentration that is different to the first salt concentration and a second dECM concentration that is different to the first dECM concentration.
  • the fibres are formed by 3-D printing of a third dECM ink of the invention.
  • the third dECM ink of the invention may have a dECM concentration and/or a salt concentration that is different to first and second dECM and salt concentrations.
  • the width (e.g. thickness) of the printed fibres may be adjusted by modifying the printing speed and/or the salt concentration of the dECM ink.
  • the printed fibres have a width of at least 100 pm and up to 1500 pm, for example 100 to 1000 pm, or 300 to 800 pm.
  • the salt concentration of the dECM ink may be varied from 0 mM up to 1 M, for example 1 to 500 mM.
  • the 3-D printing speed may be varied from 1-100 mm/s, for example 1-50, 1-30, 5-30 mm/s.
  • the implant is fibrous (e.g. it is formed by 3-D printing of a dECM ink) and exhibits a compressive modulus of greater than 60, 70, 80, 90, 100, 120, 140 or 150 KPa.
  • the invention also relates to the use of an implant of the invention to repair or replace mammalian tissue, for example articular or connective tissue, for example cartilage especially damaged cartilage, for example articular cartilage or meniscus.
  • mammalian tissue for example articular or connective tissue
  • cartilage especially damaged cartilage for example articular cartilage or meniscus.
  • the damage may be caused by trauma, disease and/or aging.
  • the damage may comprise a defect in the cartilage or meniscus.
  • the implant may be shaped to match the shape of the defect.
  • the invention also relates to a method of treating a mammalian subject by implanting an implant according to the invention into the subject.
  • the implant may replace damaged native tissue.
  • the invention also relates to a method of treating cartilage damage in a subject comprising a step of replacing all or some of the damaged cartilage with an implant according to the invention.
  • the damaged cartilage is located at a high load bearing location such as the knee.
  • the invention also relates to a method of making a decellularized extracellular matrix (dECM) ink comprising the step of mixing dECM with a solvent to provide an ink having a dECM concentration of at least 5%.
  • dECM decellularized extracellular matrix
  • the method comprises adjusting the pH of the ink to a pH of 4 to 12.
  • the method comprises adjusting the pH of the ink to a pH of 9 to 12.
  • the method comprises adjusting the pH of the ink to a pH of 10 to 12.
  • the dECM has a concentration of 5-10% (w/v).
  • the dECM has a pH of about 11.
  • the method comprises adding salt to the dECM and solvent to provide an ink having a salt concentration of 1 mM to 1M, 10 mM to 500 mM, 100 mM to 300 mM, 100 mM to 200 mM.
  • the dECM has a reduced GAG content compared to native ECM tissue.
  • the dECM is formed by a process comprising the steps of: size-reducing ECM tissue (e.g. meniscal or cartilage tissue); pretreatment of the size-reduced tissue; digestion with pepsin; dialysis with a buffer; and freeze-drying.
  • size-reducing ECM tissue e.g. meniscal or cartilage tissue
  • the pretreatment comprises treating the tissue with a surfactant (e.g. a Triton such as Triton-X-100), and/or treating the tissue with benzonase DNase.
  • a surfactant e.g. a Triton such as Triton-X-100
  • benzonase DNase e.g. a Triton such as Triton-X-100
  • the pretreatment comprises treatment with an alkali such as NaOH;
  • the size-reduced ECM tissue is subjected to one or more freeze-thaw cycles prior to the pre-treatment step.
  • the buffer is water or a weak buffer (e.g 0.2% sodium hypochlorite).
  • the dECM is formed by a process comprising the steps of: size-reducing ECM tissue (e.g. meniscal or cartilage tissue); subjecting the size-reduced tissue to one or more freeze-thaw cycles; treating the tissue with a surfactant (e.g. a Triton such as Triton-X-100); treating the tissue with benzonase DNase; acid solubilisation in acid with pepsin; dialysis with pure water; and freeze-drying.
  • a surfactant e.g. a Triton such as Triton-X-100
  • the dECM is formed by a process comprising the steps of: size-reducing ECM tissue (e.g. meniscal or cartilage tissue); pretreatment with an alkali such as NaOH; pepsin digestion; salt precipitation; dialysis with a weak buffer (e.g. 0.2% sodium hypochlorite); and freeze-drying.
  • size-reducing ECM tissue e.g. meniscal or cartilage tissue
  • pretreatment with an alkali such as NaOH
  • pepsin digestion e.g. 0.2% sodium hypochlorite
  • salt precipitation e.g. 0.2% sodium hypochlorite
  • dialysis with a weak buffer e.g. 0.2% sodium hypochlorite
  • the invention also relates to a method of making an implant comprising providing a decellularized extracellular matrix (dECM) ink, and forming an implant from the dECM ink.
  • dECM decellularized extracellular matrix
  • the dECM ink is a dECM ink of the invention.
  • the step of forming an implant from the dECM ink comprises (a) casting the dECM ink in a mould or (b) 3-D printing (e.g. extrusion printing) one or more fibres from the dECM ink, and forming the implant from the one or more 3-D printed fibres. Both steps generally result in thermal gelation of the ink and the resultant implant has the characteristics of natural cartilage or meniscus.
  • the method comprises freeze-drying the implant.
  • the method comprises crosslinking the implant.
  • the crosslinking may be chemical crosslinking with a chemical crosslinking agent
  • the crosslinking agent may be glutaraldehyde or any of the examples provided above.
  • the method comprises freeze-drying the implant and then cross-linking of the freeze-dried implant. Surprisingly, crosslinking after freeze-drying provides an implant with superior mechanical properties.
  • the 3-D printing step comprises printing a first part of the implant using a first dECM ink and printing a second part of the implant using a second dECM ink.
  • the first and second dECM inks may differ in their dECM concentration, pH, salt concentration (e.g. 0 mM up to 1 M or more). They may also differ in their method of manufacture (e.g. one ink may be formed by the Protocol 1 and the other ink may be formed by Protocol 2 as described below.
  • the 3-D printing step comprises printing a first part of the implant with a first printing protocol and printing a second part of the implant with a second printing protocol.
  • the printing protocol may differ in terms of printing speed or another parameter selected from nozzle diameter, shape and material, temperature of the cartridge and print bed, printing speed and pressure, specified scaffold geometry and infill pattern.
  • the 3-D printing step comprises printing the one or more fibres in a configuration that mimics the arrangement of fibres in natural cartilage (see Figures 4 and 5 where the fibres are printed into an arc shape mimicking the arrangement of fibres in the meniscus of the knee).
  • the implant may comprise fibres having a first configuration and fibres having a second configuration.
  • a first set of fibres may be printed to extend in a first direction or orientation (e.g. circumferential fibres) and a second set of fibres may be printed to extend in a second direction or orientation that is different to the first direction or orientation (e.g. radial fibres).
  • the first and second sets of fibres may be printed in a lattice.
  • the casting step is performed in a mould having a shape of a natural cartilage tissue, for example a medical meniscus or articular cartilage tissue.
  • the casting step comprises introducing the d-ECM at the appropriate salt concentration (150 mM) and pH (11) into a mould. Then, the cast material undergoes a degassing process, typically by introducing it into a vacuum chamber for 15 minutes. After air bubble removal, the cast material is incubated at elevated temperature, for example 4h at 37 °C before removing it from the mould. Once the embodiment is demoulded, it can be crosslinked
  • crosslinking the implant comprises immersing the implant in a crosslinking solution for a suitable period of time, for example at least 3, 6, 12, 18 or 24 house, and generally 3-48 house, 12-36 hours, or about 24 hours.
  • the crosslinking solution comprises a chemical crosslinking agent and salt.
  • the salt is the same salt that is present in the dECM and at the same or similar concentration.
  • the crosslinking solution is an aqueous solution.
  • the concentration of the chemical crosslinking agent is about 0.2% to about 1.0%, about o.3% to about 0.8%, or about 0.5% (v/v). In any embodiment, the concentration of the salt in the crosslinking solution is about IQ- 300 mM, 50-250 mM, 100-200 mM, or about 150 mM.
  • the concentration of dECM in the ink is chosen to match the ECM density of the tissue being replaced or repaired.
  • a dECM ink having a dECM concentration of about 40 - 100mg/ml is employed.
  • a dECM ink having a concentration of 30 - 100mg/ml is generally employed.
  • the concentration of dECM for casting is about 60 to 80 mg/ml, and ideally about 70 mg/ml.
  • the method comprises drying the implant. Drying may comprise freeze-drying (optionally in combination with an initial snap-freezing step). The dried implant will be rehydrated in water prior to use.
  • Figure 1 Mechanical properties of P1 dECM casted constructs, (a-c) Compression modulus, equilibrium modulus and dynamic modulus of dECM constructs at 150mM of NaCI and different pHs. (d-f) Compression modulus, equilibrium modulus and dynamic modulus of dECM constructs at pH 11 and different NaCL concentrations.
  • Figure 2 SEM imaging of d-ECM constructs, (a) Pore and (b) fiber formation within the constructs.
  • Figure 3 3D printability of dECM inks, (a) Macroscopic images of dECM inks extruded from a 25 gauge needle, (b) Printed pattern using different dECM inks. (C) Post printing spreading ratio (width of filament divided by needle diameter). ****p ⁇ .0001. (d) Printed grid structures with P1 pH11 ink. (e) 3D model of a porcine meniscus, (f) Printing path for 3D printing, (g, h) Images of printed meniscus structures using P1 pH11 ink.
  • Figure 4 Casted d-ECM meniscus. Top and front view of designed human meniscus model and cast dECM meniscus implant.
  • Figure 5 Schematics of 3D printing dECM inks to achieve alignment of collagen fibers.
  • Figure 7 Effect of the fibre alignment over the mechanical properties of the dECM ink. Comparison between the tensile properties of 3D printed dog bones, with a vertical alignment of fibres and cast dog bone specimens, without specific arrangement of the fibres. Printing improves the tensile mechanical properties of the construct.
  • Figure 8 Comparison of pre and post freeze-drying crosslinking of cast dECM in (a) compression and (b) tension tests.
  • Figure 9 Schematic of the 3D printing of a dECM meniscus implant.
  • the first layers would include circumferential fibres. Consequently, radial fibres would be interspersed within the circumferential ones. Finally, a superficial layer would be deposited or cast containing a random fibrillar network.
  • Figure 10 Effect of the freeze-drying process over the internal structure of casted and 3D printed d-ECM. Scaffolds were stained with picrosirius red before performing the freeze- drying process (Before FD), after snap freezing with subsequent freeze drying (LN + FD) and performing the freeze-drying process (After FD). Pictures were taken with polarized light (PL) and without it (Non PL).
  • Figure 11 Effect of the freeze-drying process on the tensile properties of casted and 3D printed vertical fibre-oriented d-ECM at 7% w/v.
  • the term “comprise, “ or variations thereof such as “comprises” or “comprising,” are to be read to indicate the inclusion of any recited integer (e.g. a feature, element, characteristic, property, method/process step or limitation) or group of integers (e.g. features, element, characteristics, properties, method/process steps or limitations) but not the exclusion of any other integer or group of integers.
  • the term “comprising” is inclusive or open-ended and does not exclude additional, unrecited integers or method/process steps.
  • the term “disease” is used to define any abnormal condition that impairs physiological function and is associated with specific symptoms.
  • the term is used broadly to encompass any disorder, illness, abnormality, pathology, sickness, condition or syndrome in which physiological function is impaired irrespective of the nature of the aetiology (or indeed whether the aetiological basis for the disease is established). It therefore encompasses conditions arising from infection, trauma, injury, surgery, radiological ablation, age, poisoning or nutritional deficiencies.
  • treatment refers to an intervention (e.g. the administration of an agent to a subject) which cures, ameliorates or lessens the symptoms of a disease or removes (or lessens the impact of) its cause(s) (for example, the reduction in accumulation of pathological levels of lysosomal enzymes).
  • intervention e.g. the administration of an agent to a subject
  • cures ameliorates or lessens the symptoms of a disease or removes (or lessens the impact of) its cause(s) (for example, the reduction in accumulation of pathological levels of lysosomal enzymes).
  • cause(s) for example, the reduction in accumulation of pathological levels of lysosomal enzymes
  • treatment refers to an intervention (e.g. the administration of an agent to a subject) which prevents or delays the onset or progression of a disease or reduces (or eradicates) its incidence within a treated population.
  • intervention e.g. the administration of an agent to a subject
  • treatment is used synonymously with the term “prophylaxis”.
  • an effective amount or a therapeutically effective amount of an agent defines an amount that can be administered to a subject without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio, but one that is sufficient to provide the desired effect, e.g. the treatment or prophylaxis manifested by a permanent or temporary improvement in the subject's condition.
  • the amount will vary from subject to subject, depending on the age and general condition of the individual, mode of administration and other factors. Thus, while it is not possible to specify an exact effective amount, those skilled in the art will be able to determine an appropriate "effective" amount in any individual case using routine experimentation and background general knowledge.
  • a therapeutic result in this context includes eradication or lessening of symptoms, reduced pain or discomfort, prolonged survival, improved mobility and other markers of clinical improvement.
  • a therapeutic result need not be a complete cure. Improvement may be observed in biological I molecular markers, clinical or observational improvements.
  • the methods of the invention are applicable to humans, large racing animals (horses, camels, dogs), and domestic companion animals (cats and dogs).
  • the term subject (which is to be read to include "individual”, “animal”, “patient' or “mammal” where context permits) defines any subject, particularly a mammalian subject, for whom treatment is indicated.
  • Mammalian subjects include, but are not limited to, humans, domestic animals, farm animals, zoo animals, sport animals, pet animals such as dogs, cats, guinea pigs, rabbits, rats, mice, horses, camels, bison, cattle, cows; primates such as apes, monkeys, orangutans, and chimpanzees; canids such as dogs and wolves; felids such as cats, lions, and tigers; equids such as horses, donkeys, and zebras; food animals such as cows, pigs, and sheep; ungulates such as deer and giraffes; and rodents such as mice, rats, hamsters and guinea pigs.
  • the subject is a human.
  • the term “equine” refers to mammals of the family Equidae, which includes horses, donkeys, asses, kiang and zebra.
  • extracellular matrix tissue or “extracellular matrix” or “ECM” should be understood to mean a collection of extracellular molecules secreted by cells that provides structural and biochemical support to the surrounding cells.
  • the ECM may be obtained from a mammal, for example a human or a non-human mammal, or it may be engineered in-vitro using published techniques, for example Vinardell et al (Vinardell, T., Sheehy, E., Buckley, C.T., Kelly, D.J. A comparison of the functionality and in vivo phenotypic stability of cartilaginous tissues engineered from different stem cells sources.
  • the cartilage may be micronized, which means means provided in a particulate form, in which the particles of ECM have a mean particle size of less than 200 microns as determined using routine light microscopy.
  • the micronised ECM has a mean particle size of less than 150 or 100 microns.
  • the micronized ECM has a mean particle size between 20 and 200 microns, 20 and 150 microns, 20 and 100 microns, 20 and 70 microns, 30 and 70 microns, 30 and 60 microns, 40 and 60 microns, and ideally about 50 microns.
  • Methods of micronisation include milling or cryomilling. An example of a cryomilling machine is the RETCH CRYOMILLTM.
  • the term “decellularized ECM” or “dECM” refers to ECM tissue that is digested, ideally enzymatically digested, to become soluble in an aqueous solvent and in which the cellular content of the material is reduced partially or preferably completely.
  • solubilising agents will be known to the person skilled in the art, and include enzymes and denaturing agents such as urea.
  • An example of an enzyme that can be used to digest ECM tissue to become soluble is a protease, for example pepsin, or a collagense.
  • the solubilised ECM will be a purified collagen with substantial removal of GAG and xenogeneic DNA.
  • the solubilised ECM will have greater than 50%, 60%, 70%, 80% or 90% removal of GAG and DNA when compared to native ECM tissue.
  • Methods of decellularizing ECM are described in PCT/EP2015/068855, PCT/CN2020/12374, US 20140023723, US20150344842, Tissue Engineering: Part A, 2008; 14(4) 2008: 505-518, Journal of Biomaterials Applications. 2021; 35(9): 1192-1207, Acta Biomaterialia, 2021 : 128:175-185.
  • the term “dECM ink” refers to an aqueous slurry of dECM that typically has 5% dECM (generally about 5-10% dECM) or more and typically a pH of at least 9, 10 or 11 (generally about 10-12 and ideally about 11). It may also be referred to herein as a dECM slurry or dECM hydrogel.
  • the dECM may also include a salt, for example NaCI (although other salts may be employed).
  • the salt may be included at a concentration of up to 1 M, for example 50 mM to 500 mM, 50 mM to 350 mM, 100 mM to 200 mM, or about 150 mM.
  • the dECM ink does not include a second hydrogel, e.g. does not include a hydrogel formed a component other than the dECM.
  • the term “implant” refers to a 3-D construct formed from dECM ink that is suitable for implantation into a subject to replace native tissue such as meniscus or native cartilage tissue, in particular native cartilage tissue of a joint such as a high load bearing joint, or soft tissue, especially soft tissue in high load synovial joints.
  • the implant may be formed by casting in a mould or by 3-D printing of fibres which are arranged in a 3- D shape to make up the joint.
  • the fibres in the printed implant may be arranged to mimic the orientation of fibres in natural cartilage.
  • the implant may be shaped to replace natural cartilage tissue such as articular cartilage or a meniscus.
  • Printed implants may include first fibres and second fibres that are compositionally or dimensionally different.
  • the first and second fibres may be formed from dECM that differ in terms of their dECM concentration, pH, degree or type of crosslinking, or salt concentration, which results in fibres that are compositionally or structurally different.
  • First fibres may be printed using a different printing protocol than second fibres (e.g. faster printing speed) which result in fibres with different thickness.
  • varying the dECM composition, crosslinking and printing protocols can vary the characteristics of fibres, and allowing large tissue sized meniscus implants to be fabricated that mimic the native tissue (both in terms of the micro and macro structure and mechanical properties).
  • the implant may be freeze-dried.
  • the implant may be crosslinked (e.g. chemically crosslinked).
  • the implant may be freeze-dried and then crosslinked.
  • cross-linked as applied to the implant or dECM should be understood to mean treated to introduce cross-links between different polymeric molecules in the dECM or implant.
  • Crosslinking may be performed on the dECM ink or on the formed implant.
  • the scaffold is cross-linked by one or more of the means selected from the group comprising: dehydrothermal (DHT) cross-linking; and chemical cross-linking.
  • DHT dehydrothermal
  • the crosslinking agent is typically a chemical crosslinking agent.
  • Suitable chemical crosslinking agents and methods will be well known to those skilled in the art and include a glyoxal, 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDAC) or Glutaraldehyde.
  • EDAC 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride
  • Glutaraldehyde Glutaraldehyde
  • glycosaminoglycan particularly sulphated glycosaminoglycans.
  • reduced GAG content as applied to ECM from a given source should be understood to mean a GAG content that is reduced compared to natural ECM from the same source, for example less than 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10% or 5% GAG content of natural ECM.
  • Methods of reducing GAG content include the use of buffers, detergents (such as Sodium dodecyl sulfate or Triton - X or Sodium deoxycholate) or other chemicals (e.g. chondroitinase ABC) known to reduce the sGAG content of tissues.
  • Example 1 Decell u la rised and solubilised meniscus tissue (Protocol 1)
  • Meniscus was harvested from 3 month old female pigs and diced into 1-2 mm pieces using a scalpel, followed by freeze-drying for 24 h at -10°C and cryo-milled in liquid nitrogen.
  • the powder of meniscus tissue was immersed in 10 mM Tris-HCI buffer and went through 3 freeze-thaw (-80 to 37 °C) cycles with the buffer changed every cycle.
  • the tissue was then treated with 1% triton-x100 solution for 24 h under rotation at room temperature.
  • the tissue was treated with 10 mM Tris-HCI containing 0.15 M NaCI, 2 mM MgCh and 50 ll/rnl DNase (Sigma-Aldrich, Ireland) for 24 h at room temperature with gentle agitation, followed by 2 times of freeze-thaw cycles in 50 mM Tris- HCI buffer.
  • the decellularized tissue was subsequently solubilized using a solution of 1500 ll/rnl of pepsin (Sigma-Aldrich, Ireland) in 0.5 M acetic acid under rotation for 24 h at room temperature.
  • tissue sample was then centrifuged at 2500g for 1 h to remove the insoluble material and the supernatant containing the solubilized tissue was transferred into a dialysis membrane (MWCO 12 - 14 kDa).
  • the tissue sample was dialyzed against deionized water (5L) for 48 h maximum with 3 water changes before being freeze-dried.
  • the obtained dry decellularized tissue samples were kept at -85 °C for long-term usage.
  • Example 2 Decell ula rised and solubilised meniscus tissue (Protocol 2)
  • Meniscus was harvested, freeze dried and cryo-milled as specified in the Protocol 1.
  • the freeze-dried tissue powder was then pre-treated with 0.2 M NaOH solution for 24 h at 4 °C with gentle agitation to extract the majority of sulphated glycosaminoglycan (sGAG).
  • sGAG sulphated glycosaminoglycan
  • the tissue was subsequently solubilized with pepsin as described in the Protocol 1 , followed by a centrifugation step to remove insoluble material.
  • the supernatant was combined with a 5M NaCI solution to a final concentration of 0.8 M NaCI to preferentially salt precipitate collagen from the sample.
  • the precipitated material was then solubilized again in 0.5 M acetic acid and the salt precipitation procedure was repeated a second time.
  • the acid solubilized sample was then dialyzed against 0.02 M Na 2 HPO 4 for 24 h before being lyophilized.
  • the lyophilized dry sponge was kept
  • Example 3 - dECM Slurry/ink The lyophilized dECM was stored at -85 °C. To create the slurry/ink, the required amount of material (e.g. 70mg/mL) was weighed and dissolved into 0.5M of acetic acid containing the given NaCL concentration (e.g. 150mM). The solution was rotated at 4 °C for 48 hours prior use, to ensure complete dissolution. Before use, the pH of the slurry/ink was changed accordingly by dropwise adding a solution of NaOH 10M, while maintaining the 4 °C temperature of the sample. To ensure proper homogenization of the slurry/ink, some grains of phenol red were added to the solution.
  • the required amount of material e.g. 70mg/mL
  • acetic acid containing the given NaCL concentration e.g. 150mM
  • the solution was rotated at 4 °C for 48 hours prior use, to ensure complete dissolution.
  • the pH of the slurry/ink was changed accordingly by
  • the meniscus implant was designed with the commercial software from the same company (BioCad), layer by layer.
  • the selected shape and size are similar to those found in adult native human medial meniscus: A C-shape of 46 mm large, 24mm wide and 9.5mm height.
  • the printing pattern followed a circumferential configuration.
  • the implant was incubated for 4h at 37 °C before performing the crosslinking by introducing it into a solution of 0.5% glutaraldehyde in deionized water containing the same salt concentration as the ink and adjusted to pH11. After 24h of incubation at RT, the implant was rinsed with PBS and washed thoughtfully for 4 days.
  • a 3d printed clear resin meniscus shape (Form 3, Formlabs) was designed in Solidworks with the same size and shape as specified in Example 4. From this positive geometry a negative PDMS mould was formed to provide a suitable anatomically shaped mould for casting of the d-ECM.
  • the invention uses casting or 3D printing of high concentration, decellularised meniscus ECM to produce implants that more closely mimic the structure, composition and mechanical properties of native meniscus tissue compared to existing implants. This is achieved by:
  • dECM inks were normally prepared at low concentration and neutral pH, e.g. 2% and pH 7.4, in order to maintain the cell viability when bioprinting with cells.
  • high concentration for example 5-10% dECM ink at high pH (e.g.11) to improve printability enabling the high resolution printing of large size acellular implants, as demonstrated in Figure 3, by using any of the two protocols developed for ECM decellularisation and solubilisation (P1 and P2 of Examples 1 and 2 above).
  • Anatomically shaped meniscal implants can also be produced by casting the same dECM inks (at pH 11) into preformed moulds, as demonstrated in Figure 4.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Prostheses (AREA)

Abstract

L'invention concerne un implant pour la réparation de cartilage et de ménisque et formé à partir d'encre de matrice extracellulaire de cartilage décellularisée (dECM). L'encre de dECM a une concentration de dECM de 5 à 10 % (p/v), de préférence un pH de 10 à 12, et la dECM dans l'implant est chimiquement réticulée. L'implant peut être fibreux et formé par des fibres d'impression 3D avec l'encre de dECM pour former une construction 3D fibreuse, ou il peut être formé par coulage de l'encre de dECM dans un moule. La dECM peut comprendre 50 à 350 mM de sel. Les implants constitués de dECM spécifique de tissu peuvent récapituler la niche microenvironnementale inhérente de cellules, favorisant un phénotype tissulaire spécifique. On a découvert que la lyophilisation de l'implant, puis la réticulation de l'implant lyophilisé, permettent d'obtenir un implant présentant des propriétés mécaniques améliorées.
PCT/EP2023/080806 2022-11-04 2023-11-06 Implant pour la réparation du cartilage et du ménisque WO2024094890A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263422578P 2022-11-04 2022-11-04
US63/422,578 2022-11-04
EP22207076 2022-11-11
EP22207076.5 2022-11-11

Publications (1)

Publication Number Publication Date
WO2024094890A1 true WO2024094890A1 (fr) 2024-05-10

Family

ID=88695493

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2023/080806 WO2024094890A1 (fr) 2022-11-04 2023-11-06 Implant pour la réparation du cartilage et du ménisque

Country Status (1)

Country Link
WO (1) WO2024094890A1 (fr)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880429A (en) 1987-07-20 1989-11-14 Stone Kevin R Prosthetic meniscus
US20140023723A1 (en) 2011-04-15 2014-01-23 The Regents Of The University Of California Decellularized Extracellular Matrix
US20150344842A1 (en) 2014-05-30 2015-12-03 Taipei Medical University Method for production of decellularized biological material and the decellularized biological material prepared therefrom
KR20180049712A (ko) 2016-11-03 2018-05-11 포항공과대학교 산학협력단 탈세포화 세포외 기질을 사용한 습식 3차원 세포 프린팅
KR20180125776A (ko) 2017-05-16 2018-11-26 울산과학기술원 3차원 프린팅용 바이오 잉크 조성물 및 이의 제조방법
WO2019122351A1 (fr) * 2017-12-22 2019-06-27 Cellink Ab Bioencres humaines spécifiques d'un tissu pour la bio-impression 3d physiologique de tissus humains pour une culture in vitro et une transplantation
CN111228574A (zh) 2020-01-22 2020-06-05 中国人民解放军总医院 组织工程半月板支架及其制备方法
CN112295015A (zh) 2020-02-10 2021-02-02 中国人民解放军第二军医大学 一种修复软骨缺损的生物3d打印复合墨水的制备方法

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880429A (en) 1987-07-20 1989-11-14 Stone Kevin R Prosthetic meniscus
US20140023723A1 (en) 2011-04-15 2014-01-23 The Regents Of The University Of California Decellularized Extracellular Matrix
US20150344842A1 (en) 2014-05-30 2015-12-03 Taipei Medical University Method for production of decellularized biological material and the decellularized biological material prepared therefrom
KR20180049712A (ko) 2016-11-03 2018-05-11 포항공과대학교 산학협력단 탈세포화 세포외 기질을 사용한 습식 3차원 세포 프린팅
KR20180125776A (ko) 2017-05-16 2018-11-26 울산과학기술원 3차원 프린팅용 바이오 잉크 조성물 및 이의 제조방법
WO2019122351A1 (fr) * 2017-12-22 2019-06-27 Cellink Ab Bioencres humaines spécifiques d'un tissu pour la bio-impression 3d physiologique de tissus humains pour une culture in vitro et une transplantation
CN111228574A (zh) 2020-01-22 2020-06-05 中国人民解放军总医院 组织工程半月板支架及其制备方法
CN112295015A (zh) 2020-02-10 2021-02-02 中国人民解放军第二军医大学 一种修复软骨缺损的生物3d打印复合墨水的制备方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ACTA BIOMATERIALIA, vol. 128, 2021, pages 175 - 185
BUCKLEY, C.TVINARDELL, T.KELLY, D.J.: "Oxygen Tension Differentially Regulates the Functional Properties of Cartilaginous Tissues Engineered from Infrapatellar Fat Pad Derived MSCs and Articular Chondrocytes.", OSTEOARTHRITIS AND CARTILAGE, vol. 18, no. 10, 2010, pages 1345 - 1354, XP027294621
JOURNAL OF BIOMATERIALS APPLICATIONS., vol. 35, no. 9, 2021, pages 1192 - 1207
TISSUE ENGINEERING: PART A, vol. 14, no. 4, 2008, pages 505 - 518
VINARDELL, TSHEEHY, E.BUCKLEY, C.T.KELLY, D.J.: "A comparison of the functionality and in vivo phenotypic stability of cartilaginous tissues engineered from different stem cells sources.", TISSUE ENGINEERING PART A, vol. 18, no. 11-12, 2012, pages 1161 - 1170

Similar Documents

Publication Publication Date Title
Jeznach et al. Injectable hydrogels and nanocomposite hydrogels for cartilage regeneration
Saravanan et al. Chitosan based biocomposite scaffolds for bone tissue engineering
Delgado et al. Collagen cross-linking: biophysical, biochemical, and biological response analysis
Chen et al. Three-dimensional porous gas-foamed electrospun nanofiber scaffold for cartilage regeneration
CN105169483B (zh) 一种脱细胞基质凝胶的制备方法及其脱细胞基质凝胶
JP7472051B2 (ja) 架橋タンパク質泡を発生するための粉末組成物およびその使用方法
US9101686B2 (en) Cell support and bone regeneration material
EP2345435B1 (fr) Procédé pour la fabrication d'un support poreux tridimensionnel utilisant une poudre dérivée de tissu animal, et support poreux tridimensionnel fabriqué par ce procédé
KR101027630B1 (ko) 연골 재생용 다공성 히알루론산-콜라겐 천연 고분자 지지체의 제조방법
JP5213104B2 (ja) 再生医療用バイオマテリアル
US20080026032A1 (en) Composite implants for promoting bone regeneration and augmentation and methods for their preparation and use
JPH10501155A (ja) 半月板補強装置
Chen et al. Novel chitosan hydrogel formed by ethylene glycol chitosan, 1, 6-diisocyanatohexan and polyethylene glycol-400 for tissue engineering scaffold: in vitro and in vivo evaluation
Sandri et al. Fabrication and pilot in vivo study of a collagen-BDDGE-elastin core-shell scaffold for tendon regeneration
Montaseri et al. Composite silk fibroin hydrogel scaffolds for cartilage tissue regeneration
Poveda‐Reyes et al. Reinforcing an injectable gelatin hydrogel with PLLA microfibers: Two routes for short fiber production
US20230414830A1 (en) High-Strength Collagen Sponge
Chen et al. Hyaluronic acid-based biphasic scaffold with layer-specific induction capacity for osteochondral defect regeneration
Ding et al. Cyclic freeze–thaw grinding to decellularize meniscus for fabricating porous, elastic scaffolds
Abpeikar et al. Development of meniscus cartilage using polycaprolactone and decellularized meniscus surface modified by gelatin, hyaluronic acid biomacromolecules: a rabbit model
Barroso et al. Photocurable antimicrobial silk‐based hydrogels for corneal repair
Wu et al. Nature‐Inspired Strategies for the Treatment of Osteoarthritis
Anjum et al. Exploring polysaccharide and protein-enriched decellularized matrix scaffolds for tendon and ligament repair: a review
JP2023517179A (ja) 脱細胞化生体材料を製造する方法、脱細胞化生体材料、及びその使用
WO2024094890A1 (fr) Implant pour la réparation du cartilage et du ménisque

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23800857

Country of ref document: EP

Kind code of ref document: A1